These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 30536571)
1. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571 [TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer. Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133 [TBL] [Abstract][Full Text] [Related]
3. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro. Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674 [TBL] [Abstract][Full Text] [Related]
4. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507 [TBL] [Abstract][Full Text] [Related]
5. New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells. Buľková V; Vargová J; Babinčák M; Jendželovský R; Zdráhal Z; Roudnický P; Košuth J; Fedoročko P Biomed Pharmacother; 2023 Jul; 163():114829. PubMed ID: 37146419 [TBL] [Abstract][Full Text] [Related]
6. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195 [TBL] [Abstract][Full Text] [Related]
8. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance. Vukovic M; Guitart AV; Sepulveda C; Villacreces A; O'Duibhir E; Panagopoulou TI; Ivens A; Menendez-Gonzalez J; Iglesias JM; Allen L; Glykofrydis F; Subramani C; Armesilla-Diaz A; Post AE; Schaak K; Gezer D; So CW; Holyoake TL; Wood A; O'Carroll D; Ratcliffe PJ; Kranc KR J Exp Med; 2015 Dec; 212(13):2223-34. PubMed ID: 26642852 [TBL] [Abstract][Full Text] [Related]
9. Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition. Hallis SP; Kim SK; Lee JH; Kwak MK Redox Biol; 2023 Apr; 60():102632. PubMed ID: 36791645 [TBL] [Abstract][Full Text] [Related]
10. Differential expression of hypoxia-inducible factors related to the invasiveness of epithelial ovarian cancer. Shih HJ; Chang HF; Chen CL; Torng PL Sci Rep; 2021 Nov; 11(1):22925. PubMed ID: 34824343 [TBL] [Abstract][Full Text] [Related]
11. HIF-1α forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells. Zhu B; Pan S; Liu J; Wang S; Ni Y; Xiao L; Wei Q; Peng Y; Ding Z; Zhao W Cell Biol Int; 2020 Feb; 44(2):456-466. PubMed ID: 31617641 [TBL] [Abstract][Full Text] [Related]
12. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Zhang Q; Lou Y; Zhang J; Fu Q; Wei T; Sun X; Chen Q; Yang J; Bai X; Liang T Mol Cancer; 2017 Jul; 16(1):119. PubMed ID: 28705232 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Cui XY; Skretting G; Jing Y; Sun H; Sandset PM; Sun L Blood Cells Mol Dis; 2013 Oct; 51(3):177-84. PubMed ID: 23725749 [TBL] [Abstract][Full Text] [Related]
15. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors. Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728 [TBL] [Abstract][Full Text] [Related]
17. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy. Pastorek M; Simko V; Takacova M; Barathova M; Bartosova M; Hunakova L; Sedlakova O; Hudecova S; Krizanova O; Dequiedt F; Pastorekova S; Sedlak J Int J Oncol; 2015 Jul; 47(1):51-60. PubMed ID: 25955133 [TBL] [Abstract][Full Text] [Related]
19. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process. Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849 [TBL] [Abstract][Full Text] [Related]
20. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]